Detailed explanation of the research and development process, latest market price and purchasing channels of giritinib

Acute myeloid leukemia (AML) is a serious hematological malignancy, in which approximately 30% of patients have FLT3 gene mutations. These mutations cause leukemia cells to proliferate abnormally and are difficult to control, and traditional treatments often have limited effectiveness. It is against the backdrop of this urgent need that giritinib emerged. Its research and development is based on in-depth exploration of the mutation mechanism of FLT3 gene. It aims to effectively block the signaling pathway of leukemia cells by specifically inhibiting FLT3 kinase activity and bring new treatment hope to patients. The clinical performance of giritinib is exciting. It not only has a significant inhibitory effect on FLT3-ITD mutations, but also exerts an inhibitory effect on FLT3-TKD mutations, bringing new treatment hope to AML patients around the world.

Since its launch, giritinib has received widespread attention due to its excellent clinical efficacy and good safety profile. However, the market price of the drug has also become the focus of many patients. In the Chinese market, a box of gilitinib with a specification of 40 mg 21 tablets 2 tablets sells for tens of thousands of yuan. Since the drug has not yet been included in the medical insurance list, patients need to purchase it at their own expense, which undoubtedly puts heavy financial pressure on most patients. For patients with limited financial conditions, considering purchasing overseas generic drugs has become a feasible option. In Laos, generic drugs of giritinib are already on the market, and the price is relatively affordable. For example, the Lucius version of the drug is priced at just over 2,000 yuan per box (40mg*90tablets), which greatly reduces the financial burden on patients.

For patients who need to purchase giritinib, it is important to know the correct purchasing channel. Original medicines can currently be purchased in regular domestic hospitals or pharmacies with a doctor’s prescription. For generic drugs, you can consult some professional overseas medical institutions. They usually have direct contact with pharmaceutical manufacturers and can ensure the reliability of the source of the drugs. At the same time, patients should remain vigilant when purchasing medicines and pay attention to identify the authenticity of the medicines. If there is any doubt, do not use them.

In general, as a targeted drug targeting FLT3 mutation-positive AML, giritinib’s research and development process, market price and purchase method are worthy of in-depth understanding and attention by patients and medical workers. When choosing purchasing channels, patients should remain rational, ensure that they are purchasing genuine drugs, and seek advice and help from professional medical professionals as much as possible.